| |
CF patients
|
| |
n
|
|
Total
|
930
|
|
P. aeruginosa pos.
|
292
|
|
P. aeruginosa MDR pos.a
|
49 (=16.8% of P. aeruginosa pos.)
|
| |
MDR P. aeruginosa, b
|
| |
n
|
%
|
|
Agec
|
|
0–10
|
3
|
11
|
|
11–20
|
2
|
7
|
|
21–30
|
10
|
36
|
|
31–40
|
7
|
25
|
|
41–50
|
2
|
7
|
|
> 51
|
4
|
14
|
|
Resistance to d
|
|
Colistin
|
5
|
17
|
|
Fosfomycin
|
20
|
69
|
|
Aztreonam
|
29
|
100
|
|
Gentamicin
|
27
|
93
|
|
Tobramycin
|
18
|
62
|
|
Amikacin
|
25
|
86
|
|
Carriage status e
|
|
Intermittent
|
1
|
4
|
|
Chronic
|
27
|
96
|
- a defined as combined resistance to piperacillin/tazobactame, ceftazidime, imipenem, meropenem and ciprofloxacin
- b N = 29 isolates from N = 28 patients, i.e. one patient had two morphologically distinct isolates
- c median age 27.5 years (range 7 to 70 years); n = 28 patients
- d categorized as resistant (i.v. application) if MIC interpreted as intermediate or resistant
- e chronic: > 50% P. aeruginosa positive samples within 12 months; intermittent: < 50% P. aeruginosa positive samples within 12 months; negative: > 1 year P. aeruginosa negative
